Althea Group Holdings Ltd banner

Althea Group Holdings Ltd
ASX:AGH

Watchlist Manager
Althea Group Holdings Ltd Logo
Althea Group Holdings Ltd
ASX:AGH
Watchlist
Price: 0.017 AUD Market Closed
Market Cap: AU$17m

P/B

-29.7
Current
149%
Cheaper
vs 3-y average of 60.6

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
-29.7
=
Market Cap
AU$17m
/
Total Equity
AU$-574k

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
-29.7
=
Market Cap
AU$17m
/
Total Equity
AU$-574k

Valuation Scenarios

Althea Group Holdings Ltd is trading above its 3-year average

If P/B returns to its 3-Year Average (60.6), the stock would be worth AU$-0.03 (304% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-304%
Maximum Upside
No Upside Scenarios
Average Downside
209%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple -29.7 AU$0.02
0%
3-Year Average 60.6 AU$-0.03
-304%
5-Year Average 60.6 AU$-0.03
-304%
Industry Average 5.8 AU$-0
-120%
Country Average 2.7 AU$-0
-109%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close
Market Cap P/B P/E
AU
Althea Group Holdings Ltd
ASX:AGH
17m AUD -29.7 -2
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 31.5 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 6.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 7.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 5.9 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 5.9 19.6
US
Merck & Co Inc
NYSE:MRK
276.9B USD 5.3 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD -58.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 6 11.3
US
Pfizer Inc
NYSE:PFE
153.5B USD 1.8 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 6.4 16.8
P/E Multiple
Earnings Growth PEG
AU
Althea Group Holdings Ltd
ASX:AGH
Average P/E: 21.9
Negative Multiple: -2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Lower than 100% of companies in Australia
Percentile
0th
Based on 2 062 companies
0th percentile
-29.7
Low
0 — 1.6
Typical Range
1.6 — 4.3
High
4.3 —
Distribution Statistics
Australia
Min 0
30th Percentile 1.6
Median 2.7
70th Percentile 4.3
Max 2 199.4

Althea Group Holdings Ltd
Glance View

Market Cap
17m AUD
Industry
Pharmaceuticals

Althea Group Holdings Ltd. is an investment company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-09-21. The firm operates through three segments: Australia, United Kingdom and Canada. Australia segment provides technology platform, which is comprised of its on-the-ground Medical Science Liaison team and Althea Concierge, which reduces application times for healthcare professionals prescribed its medicinal cannabis products. The firm distribution and sale of Cannabis 2.0 products including edibles, topicals, and beverages through its subsidiary, Peak Processing Solutions.

AGH Intrinsic Value
0.041 AUD
Undervaluation 59%
Intrinsic Value
Price AU$0.017
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett